FlowMetric Europe Headquarters Moves to Zambon OpenZone Campus
FlowMetric Europe, a wholly owned subsidiary of FlowMetric Life Sciences, is excited to announce that it will be opening its expanded European Headquarters office within the OpenZone campus (www.openzone.it), effective January 28th, 2019. The OpenZone scientific campus, a center of excellence for research and innovation located in Bresso, Italy is fully dedicated to the Life Sciences, has over 7,500 square meters of laboratory space, and hosts 22 companies focused on the biotechnology, pharmaceutical, and advanced gene therapy fields.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190108005310/en/
The new FlowMetric Europe Headquarters will be located within the Zambon OpenZone Campus at Via Antonio Meucci, 3, 20091 BRESSO (MI), a short distance from Milan center city. (Photo: Business Wire)
Mr. Renold Capocasale, founder and CEO of FlowMetric Life Sciences, is thrilled about the move and commented that "our global business has grown quickly and by relocating to a scientifically innovative and vibrant campus dedicated to the Life Sciences, while also increasing our office and lab space, will allow us to continue to grow our successful full-service flow cytometry CRO."
The new headquarters, containing three laboratories and offices, will be equipped with high dimensional flow cytometry instruments as well as a full tissue culture suite, in order to provide quality flow cytometry and cell sorting services to FlowMetric Europe’s European clients in the preclinical and clinical phases of development.
“We have a strong team here in Italy, true experts and industry leaders in the flow cytometry field,” notes Mr. Gianluca Carenzo, Vice President of FlowMetric Europe. “This move and expansion is necessary to support our continued client requests for additional global clinical trials in the EU.”
The FlowMetric Europe facilities will be located at Via Antonio Meucci, 3, 20091 BRESSO (MI), a short distance from Milan center city.
About FlowMetric Life Sciences
The FlowMetric Life Sciences family of companies is driven to provide Flow Cytometry Solutions in Precision Medicine. FlowMetric and FlowMetric Europe are a full service Flow Cytometry and Cell Sorting contract research organization. The company provides services for global partners in multiple therapeutic areas as well as throughout every phase of pharmaceutical development (preclinical research, non-GLP and GLP Toxicology studies as well as Clinical Phase 0-IV trials). Building on a combined 100 years of expertise in flow cytometry and advanced analysis platforms, FlowMetric Life Sciences adds value across the spectrum of drug discovery, translational research and clinical trials.
OpenZone is a campus dedicated to Life Sciences created by Zambon to perform research in an approach based on open innovation. Conceived with the mission of creating an entrepreneurial ecosystem to promote the exchange of knowledge and give rise to collaborations, the campus now accommodates over 20 companies, including some of the leading biotech, pharmaceutical and advanced gene therapy companies that are strongly oriented towards research and innovation, with internationally known and qualified experts. Thanks to an investment of 60 million Euros, OpenZone will double the existing space and number of laboratories by 2020, to a total area of 37,000 square meters that will provide space for up to 1,200 people.
FlowMetric Life Sciences
Rachel Bunting, MS, MBA
VP, Global Sales & Marketing
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Piraeus Bank Presents the Principles for Responsible Banking with the Governor of the Bank of Greece16.1.2019 18:21 | Pressemelding
The Principles for Responsible Banking were presented today for the first time in Greece at an event organized by Piraeus Bank with Mr. Yannis Stournaras, the Governor of the Bank of Greece, as the keynote speaker. The event was organised as part of Piraeus Bank’s commitment to the United Nations Environment Programme Finance Initiative (UNEP FI). Piraeus is the only Greek bank to be a member of the global initiative, which includes twenty-eight banks from around the world, representing over USD 17 trillion in combined assets. Mr. Yannis Stournaras, the Governor of Bank of Greece, highlighted in his speech that the Bank of Greece fully supports the Principles for Responsible Banking and urges all of the banks to endorse the Principles and set ambitious targets. The Bank of Greece was one of the first central banks to become involved with the climate change issue, establishing the Climate Change Impacts Study Committee in 2009 and investing in one of the most significant Sustainable Dev
Arrowgrass Has Agreed to an Extension of Its Irrevocable Undertaking Regarding Its Holdings in Basware Corporation16.1.2019 17:30 | Pressemelding
The investment funds of Arrowgrass Capital Partners LLP (“Arrowgrass”) hold, directly and indirectly, over 24 per cent of all shares and votes in Basware Corporation (“Basware”), a Finnish listed company providing networked source-to-pay solutions and e-invoicing services. Arrowgrass refers to the announcements made by Basware on 16 November 2018, 20 November 2018 and 7 December 2018 with regard to a possible tender offer by Tradeshift Holdings Inc. (“Tradeshift”) for Basware. Arrowgrass announces that it has agreed, under certain conditions, to extend an irrevocable undertaking with Tradeshift to accept a tender offer by Tradeshift for Basware, should Tradeshift publicly announce its tender offer in accordance with applicable laws and regulations no later than 28 February, 2019. Arrowgrass recognizes that Basware has emphasized in its announcements that the launch of the tender offer remains uncertain. About Arrowgrass Arrowgrass Capital Partners LLP is a London headquartered alternat
PCI Security Standards Council Publishes New Software Security Standards16.1.2019 15:25 | Pressemelding
Today, the PCI Security Standards Council (PCI SSC) published new requirements for the secure design and development of modern payment software. The PCI Secure Software Standard and the PCI Secure Lifecycle (Secure SLC) Standard are part of a new PCI Software Security Framework, which includes a validation program for software vendors and their software products and a qualification program for assessors. The programs will be launched later in 2019. “Innovation in payments is moving at an incredible pace. Each advancement provides the industry the opportunity to develop applications more quickly and efficiently than before and to design software for new platforms for payment acceptance,” said PCI SSC Chief Technology Officer Troy Leach. “The new PCI Secure Software Standard and PCI Secure SLC Standard support this evolution in payment software practices by providing a dynamic way for developers to demonstrate their software protects payment data for the next generation of applications.”
Keio Plaza Hotel Hosts “Hina-matsuri (Girls’ Doll Festival)” Event – 6,800 Magnificent Hanging Art Ornaments and Tea Ceremony Culture16.1.2019 14:05 | Pressemelding
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host an event entitled “Hina-matsuri through Tea Ceremony Culture and Hanging Art” to help guests celebrate Japan’s cultural event known as Girls’ Doll Festival or “Hina-matsuri” from February 1 (Friday) to March 28 (Thursday), 2019 with magnificent hanging art ornaments displayed in our lobby and special menu items served in our restaurants. In addition to the display of some 6,800 magnificent and ornate handmade dolls and other traditional decorations in this coming event, our Hotel will also display various traditional and historical art items used in traditional Japanese tea ceremony, which has long been a part of the cultural upbringing of Japanese women from the Meiji Period (1868 to 1912). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005191/en/ About 6,800 hanging decorative art ornaments meticul
Virgin Voyages Calling All RockStars to Sea16.1.2019 14:00 | Pressemelding
Virgin Voyages, the new lifestyle brand set to disrupt the travel industry, today released several designs and images of their RockStar Suites. The new company is throwing out traditional clichés on luxury and formalities, and instead bringing Rebellious Luxe to life at sea with their RockStar Suites designed by Tom Dixon’s Design Research Studio as the pinnacle of that experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005444/en/ Massive Suite Living Room. (Photo: Business Wire) Highlights of the Massive Suite, the top suite aboard the Scarlet Lady, include its very own guitar-clad music room, views of the ocean from every corner of the suite, and a massive terrace complete with its own Peek-a-View outdoor shower, hot tub, hammocks and a runway outdoor dining table, where a staircase will help Sailors make their way on top of the table for dancing. “Virgin has always avoided stuffy formalities and brought a lo
Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease16.1.2019 13:24 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. The EC approval is based on data from the pivotal Phase 3 SPARTAN study, which was published in The New England Journal of Medicine. The study assessed the efficacy and safety of apalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with nmCRPC who had a rapidly rising prostate specific antigen (PSA) level despite receiving continuous ADT. Findings from the study showed that apalutamide plus ADT, significantly reduced the risk of developing distant metastasis or death (metastasis free survival [MFS]) by 72 percent, compared to placebo in combination with ADT (HR = 0.28; 95% CI, 0